Navigation Links
TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials

ents discontinued treatment for any reason vs. 73 in the placebo arm.

Most of the rashes seen with TMC125 were mild to moderate in severity, occurred within the first few weeks of treatment and resolved with continued TMC125 treatment. Grade 3 or 4 rash occurred in 1 percent of patients in the TMC125 arm and no patients in the placebo arm.

DUET-1 and -2 Study Design

The DUET studies are double-blind, placebo-controlled, international Phase 3 trials designed to assess the efficacy and safety of TMC125 in treatment- experienced adult HIV-1 patients with documented evidence of NNRTI and PI resistance. Participants were randomized to receive TMC125 200 mg twice daily or placebo, each given in addition to a BR.

In both studies, patient randomization was stratified for enfuvirtide use in the BR (no use, re-use, or first time use), previous darunavir use (used or not), and screening plasma viral load (<30,000 or >=30,000 copies per mL).

Patients with HIV-1 who were eligible for the DUET trials had a viral load of greater than 5,000 copies/mL, were on a stable antiretroviral therapy regimen, and had evidence of at least one NNRTI-resistance-associated mutation, either at screening or from historical resistance tests as well as evidence of three or more primary PI mutations at screening.

TMC125 Expanded Access Program

The expanded access program (EAP) for TMC125 is now open in a number of European countries, Canada and the United States. TMC125 is available to HIV-1 infected adults, at least 18 years old, who have limited treatment options either due to virological failure or intolerance to multiple ARV regimens. Patients must be three-class experienced, having received licensed treatment from each of the three major oral classes of anti-HIV drugs (NRTIs, NNRTIs, and PIs), unable to use currently approved NNRTIs due to resistance and/or intolerance and have received at least two PI-based regimens.

For more about the pro
'"/>




Page: 1 2 3 4

Related medicine technology :

1. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
5. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
6. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
7. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
8. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
9. Laquinimod, a Novel Oral Compound, Showed Significant Reduction in Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)
10. OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
11. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
Post Your Comments:
(Date:7/25/2014)... -- Leading events organizer UBM Live announces that ... year to São Paulo, Brazil from ... event will co-locate with Food Ingredients South America (FiSA), creating ... for the pharmaceutical industry.      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... are now exploring the South America ...
(Date:7/25/2014)... SAN DIEGO , July 25, 2014  Arena ... it will provide a corporate update and report second ... Market opens on Friday, August 1, 2014. That same ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). ... by dialing 877.643.7155 for domestic callers and 914.495.8552 for ...
(Date:7/24/2014)... , July 24, 2014   AcelRx Pharmaceuticals, Inc. ... focused on the development and commercialization of innovative therapies ... confirmed the PDUFA date for Zalviso remains July 27, ... rumor circulated online stating the Food and Drug Administration ... there has been no notification to the company from ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
... 19, 2007 - Acorda,Therapeutics (Nasdaq: ACOR) today announced ... Center at the University,of Rochester, will present data ... in multiple sclerosis at the,upcoming American Academy of ... on Wednesday May 2, 2007 at 4:15 pm,Eastern ...
... Full Study Results,to Be Presented at the American ... ,WIRE) -- 03/19/2007 -- AtheroGenics, Inc. (NASDAQ: AGIX) ... of its lead drug,candidate, AGI-1067, did not show ... however, it did achieve a number of,other important ...
Cached Medicine Technology:Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data,Selected for Scientific Highlights Program at the American Academy,of Neurology Meeting 2AtheroGenics Reports ARISE Trial Results for AGI-1067 2AtheroGenics Reports ARISE Trial Results for AGI-1067 3AtheroGenics Reports ARISE Trial Results for AGI-1067 4
(Date:7/25/2014)... July 26, 2014 2014 Deep ... Confocal Microscope Industry” is a professional and ... Confocal Microscope market. The report provides basic ... Scanning Confocal Microscope definition, classification, application, and ... This research covers international market analysis, including China’s ...
(Date:7/25/2014)... 25, 2014 American motor vehicle owners ... collisions can pay higher premiums for vehicle insurance on ... insurer network to provide SR22 insurance for high risk ... The different coverage network of local agencies providing direct ... search platform now publicly available for any car owner ...
(Date:7/25/2014)... USA (PRWEB) July 25, 2014 As reported ... of Dangerous Synthetic Marijuana Increasing (7/3), the state of ... synthetic marijuana, more so even than cocaine. Officials believe the ... safe because it's a “form” of marijuana. However, both doctors ... truth. Going so far as to call it “poison,” doctors ...
(Date:7/25/2014)... FRIDAY, July 25, 2014 (HealthDay News) -- Seniors are ... younger people, a new study finds. "Almost any ... memory from the age of 25 on," study co-author ... in a university news release. However, Martin said, ... impact on processing in older adults compared with younger ...
(Date:7/25/2014)... As reported by Wood TV 8 in ... Michigan has seen a nearly 500-person increase in heroin related ... was 271 between 1999 and 2002, the toll increased to ... like other states, drug users in Michigan have turned to ... He compared the price of both substances, noting that an ...
Breaking Medicine News(10 mins):Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 2Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 3Health News:Laser Scanning Confocal Microscope Market: 2014 Global, China Manufacturing Bases Analysis Now at DeepResearchReports.com 4Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Distractions Seem More Troublesome With Age 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2
... executives who have almost 50 years of hospital negotiating experience. Our ... a focus of expertise to help buyers become even more effective. ... all hospital purchases. There is finally help. , ... ...
... rituximab causes considerable kidney injury healing in patients with ... to a study appearing in the November 2008 issue ... Nephrology (CJASN) . The results suggest that this condition, ... percent of cases, can actually be healed in some ...
... Ill., Aug. 5 Healthation CEO Scott Kornhauser,announced ... Services. Collins brings to Healthation more than 20 ... include Vice President of Professional Services of,Aptiv Technology ... will be focused on leading, recruiting, and managing ...
... of Princeton psychology researchers has developed a computer program ... what it is about certain human faces that makes ... they have also found that the program allows them ... or dominant faces possible. , Such work could have ...
... carts from Eagle MHC are designed for maximum cleanability and sterile ... ... -- http://www.eaglegrp.com/ [Steril-Eze® surgical case carts] from Eagle MHC ... product line - which encompasses a wide range of choices in ...
... (NPF) announced it will fund $3.7 million in ... outreach worldwide.,Grants were awarded to institutions in the ... care centers, and 10 outreach,centers. Through centers alone, ... and almost 70,000 patients with movement disorders., ...
Cached Medicine News:Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 2Health News:Anderson Consulting Group (ACG) Announces "The Art of Hospital Negotiation" -- Strategies & Tactics for Materials Management Course Exclusively for Hospital Personnel 3Health News:Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease 2Health News:Whom do we fear or trust? 2Health News:Whom do we fear or trust? 3Health News:New Steril-Eze Surgical Case Carts from Eagle MHC Feature Rugged, Easy-Clean Design 2Health News:National Parkinson Foundation Awards $3.7 Million in Grants 2
... and Only 16-Electrode Non-Rechargeable ... of RESTORE with the convenience of ... unrivaled RESTOREPRIME. The ultimate non-rechargeable device, ... managing patients with bilateral and complex ...
... a rechargeable neurostimulator equipped with a battery ... a 9-year FDA approved battery life. It ... market. This is helpful to people who ... What makes RESTOREADVANCED and PRIMEADVANCED different from ...
... is an acellular dermal matrix derived from ... AATB-compliant tissue banks utilizing the standards of ... and Food and Drug Administration's (FDA) guidelines. ... and not significantly changed in structure from ...
... a modular external fixation system designed to ... clinical needs. Originally marketed in Europe under ... 20 year history of clinical use in ... principles of the Ilizarov technique begun in ...
Medicine Products: